SCYNEXIS (NASDAQ: SCYX) and Impax Laboratories (NASDAQ:IPXL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Earnings & Valuation

This table compares SCYNEXIS and Impax Laboratories’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
SCYNEXIS $256,999.00 250.58 -$25.04 million N/A N/A
Impax Laboratories $812.82 million 1.79 $144.42 million ($8.07) -2.52

Impax Laboratories has higher revenue and earnings than SCYNEXIS.

Profitability

This table compares SCYNEXIS and Impax Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SCYNEXIS -9,648.47% -64.04% -37.19%
Impax Laboratories -71.08% 9.05% 3.20%

Institutional & Insider Ownership

36.8% of SCYNEXIS shares are owned by institutional investors. Comparatively, 86.3% of Impax Laboratories shares are owned by institutional investors. 4.0% of SCYNEXIS shares are owned by company insiders. Comparatively, 3.2% of Impax Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

SCYNEXIS has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Impax Laboratories has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for SCYNEXIS and Impax Laboratories, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS 0 1 6 1 3.00
Impax Laboratories 1 9 5 0 2.27

SCYNEXIS currently has a consensus price target of $11.25, indicating a potential upside of 366.80%. Impax Laboratories has a consensus price target of $19.67, indicating a potential downside of 3.12%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than Impax Laboratories.

Summary

Impax Laboratories beats SCYNEXIS on 7 of the 13 factors compared between the two stocks.

About SCYNEXIS

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

About Impax Laboratories

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.